Diets low in carbohydrates and soluble fibres can drive the growth of polyps in the colon, increasing the risk of developing ...

Selective degradation of ARID1B achieved. Earlier this year, Foghorn announced that the company has achieved selective degradation of ARID1B and will provide a program update during 2025.

Clinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored “window of opportunity” trial into newly diagnosed ...

The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 ...

Ovarian cancer, known for its subtle symptoms, claims thousands of lives annually. Risk factors include age, genetic ...

In a groundbreaking clinical trial, immunotherapy alone eliminated rectal cancer in all 14 participants. This study, the ...

Scientists from UCLA, the University of Toronto and the University of Melbourne have uncovered new genetic clues that explain why some prostate cancer remain slow-growing while others become ...

Pancreatic cancer remains one of the most challenging tumors to treat, partly because it is often discovered at advanced ...

Updated ASCO guidelines for pleural mesothelioma refine surgery use, recommend immunotherapy, genetic testing, and improve ...

Jaxon Kenkel is a happy-go-lucky, 5-year-old boy, your typical baseball and hockey-loving youngster. He doesn’t know he has ...

At the heart of the deal is the drug candidate dordaviprone, which is months away from a regulatory verdict for its use in H3 ...